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Summary 
It has been proposed that apoptosis is one of the mecha-
nisms involved in the generation of antiphospholipid antibod-
ies. The presence of antiphospholipid antibodies is the main
laboratory criterion for a definite diagnosis of the antiphos-
pholipid syndrome. Annexinopathies are disorders character-
ized by deregulation of annexins expression levels and func-
tion. Annexin A5 has been used as an agent for molecular
imaging techniques (visualization of phosphatidylserine-
expressing apoptotic cells) in vitro and in vivo in animal mo -
dels and in patients (injection of human recombinant anxA5
into the patient‘s circulation). Although the determination of
titers of anti-annexin A5 antibodies is not mandatory for the
diagnosis of the antiphospholipid syndrome, it was reported
that patients with primary antiphospholipid syndrome with a
history of recurrent abortions had elevated titers of anti-
annexin A5 antibodies, while the presence of thromboses
was not associated with elevated levels of these antibodies. 
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Kratak sadr`aj
Apoptoza je predlo`ena kao jedan od mehanizama
uklju~enih u generisanje antifosfolipidnih antitela. Prisustvo
antifosfolipidnih antitela glavni je laboratorijski kriterijum za
dijagnozu definitivnog antifosfolipidnog sindroma. Anek si -
nopatije su poreme}aji koji se karakteri{u deregulacijom
nivoa ekspresije aneksina i njihove funkcije. Aneksin A5 se
koristio kao agens za tehnike molekularnog snimanja (vi -
zuelizacija apoptoti~nih }elija koje ispoljavaju fosfati dilserin)
in vitro i in vivo u animalnim modelima i kod pacijenata
(injektovanje humanog rekombinantnog aneksina A5 u
cirkulaciju). Iako odre|ivanje titra antitela anti-aneksina A5
nije obavezno za dijagnozu antifosfolipidnog sindroma, pri-
javljeni su slu~ajevi pacijenata sa primarnim antifosfolipidnim
sindromom i istorijom spontanih poba~aja koji su imali po -
vi{ene titre antitela anti-aneksina A5, dok prisustvo tromboza
nije bilo povezano sa povi{enim nivoima ovih antitela. 
Klju~ne re~i: apoptoza, aneksin A5, antitela anti-aneksi-
na A5, antifosfolipidni sindrom
Antiphospholipid Syndrome
Antiphospholipid syndrome (APS) is an autoim-
mune disease that is characterized by thromboses
(arterial and/or venous) and/or the presence of
recurrent miscarriages associated with the presence
of antiphospholipid antibodies (aPL) (1). It may be
primary (PAPS) or secondary antiphospholipid syn-
drome, when it is associated with another disease.
According to the revised and updated criteria for the
diagnosis of the APS, the presence of at least one
clinical and one laboratory criterion is necessary for
the diagnosis of definite APS (2). Clinical criteria are
the presence of thromboses (arterial and/or venous)
and/or the presence of pathological pregnancies.
Laboratory criteria are: the presence of IgG and/or
IgM anticardiolipin antibodies in medium and high
titers, anti-b2glycoprotein I (b2gpI) antibodies of IgG
and/or IgM class and/or the presence of lupus anti-
coagulant (2).
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Antiphospholipid antibodies are a heterogenous
group of antibodies, and originally it was supposed
that these antibodies were directed against negative-
ly charged phospholipids. Also, it was thought that
these phospholipids are a specific subset of lipids that
play a crucial role in the coagulation cascade (3, 4).
Previously, it was proposed that apoptosis (pro-
grammed cell death) is one of the mechanisms
responsible for the generation of antiphospholipid
antibodies (5). 
Apoptosis is characterized by DNA cleavage,
nuclear condensation and fragmentation, changes in
membrane lipid distribution, detachment of cells from
the extracellular matrix, and these transformations
result in the phagocytosis of cells. This type of cell
death is in contrast with necrosis (plasma membrane
integrity is impaired and cellular contents are enzy-
matically degraded and released, which results in
pathological inflammation) (6). 
Exposure of phospholipids during apoptosis pro-
vides an antigenic stimulus for the production of
antiphospholipid autoantibodies. In addition, the
phospholipid–protein complexes formed during apop-
tosis are targeted by pathogenic antiphospholipid
antibodies (7). 
Phospholipids – Components of Cell
Membranes
The lipid composition of the inner and the outer
leaflet of the plasma membrane is different. 
The inner, cytoplasmatic leaflet is mainly com-
posed of aminophospholipids (phosphatidylserine and
phosphatidylethanolamine), while cholinephospho-
lipids (sphingomyelin and phosphatidylcholine) com-
prise the outer leaflet of the plasma membrane. 
The maintenance of the membrane asymmetric
distribution of lipids is crucial for normal cell functions
(8). The lipid asymmetry of the plasma membrane is
maintained by an energy-dependent lipid transport
mechanism. Translocase activity is ATP-dependent
and involves inward movement of phosphatidylserine
and phosphatidylethanolamine to the inner side of
the plasma membrane, while floppase activity is also
ATP-dependent and promotes outward movement of
both aminophospholipids and cholinephospholipids
(9). During apoptosis (10), phosphatidylserine moves
from its physiological location in the inner leaflet of
the plasma membrane to the outer leaflet (11).
Modification of the plasma membrane phosp ho -
lipid distribution is an event that provides a signal
related to different mechanisms occurring in various
pathophysiological processes, such as the activation
of the coagulation cascade, recognition and removal
of the apoptotic cells. Exposure of phosphatidylserine
on apoptotic cell membranes has two functional pro -
perties. Firstly, it contributes to the activation of the
coagulation factors (IX, VIII, X, V, II) and the genera-
tion of thrombin. Secondly, it acts as a recognition
signal for macrophages which are involved in the
clearance of apoptotic cells (12). The following anti-
gen processing and presentation by antigen present-
ing cells provide an antigenic stimulus to specific
clones of T-lymphocytes and B-lymphocytes which
leads to production of antiphospholipid antibodies.
These antibodies en hance the immune response to
phospholipid–protein com plexes by promoting an
antibody-mediated pha gocytosis (7). 
Cardiolipin is a phospholipid that is located in
the inner mitochondrial membrane (13). During
death receptor-mediated apoptosis, cardiolipin and its
metabolites shift from mitochondria to other orga nel -
les and to cell surface (14). Changes in the distribu-
tion of cardiolipin occur before or during membrane
exposure of phosphatidylserine (15). 
Cardiolipin is the most highly unsaturated lipid
in the human body (16). It is composed of two phos-
phate groups and four fatty acid chains (16).
Cardiolipin metabolites generated by rapid deacyla-
tion (mono lysocardiolipin and dilysocardiolipin) are
transported to endoplasmic reticulum for reacylation.
The number of acyl chains in cardiolipin derivatives is
important for the binding of b2gpI to phospholipids
and for the generation of epitopes of anticardiolipin
antibodies for specific cardiolipin metabolites.
Hydroperoxidation of cardiolipin is essential for
enhancing its binding with antiphospholipid antibod-
ies (17). Apoptosis can lead to cell surface exposure
of cardiolipin and monolysocardiolipin which might
become targets for antiphospholipid antibodies. The
clinical features of the APS may be related to a dear -
rangement of cardiolipin metabolism. 
Endothelial cells and monocytes are cellular tar-
gets for antiphospholipid antibodies. Treatment of
these cells with TNF-alpha seems to enhance the
binding of antibodies directed to endothelial epitopes
(18). 
Interaction of antiphospholipid antibodies with
endothelial cells can trigger an inflammatory res -
ponse (19). Stimuli capable of triggering apoptosis
can also generate reactive oxygen species (ROS).
Cells exposed to ROS precursor can undergo death
with apoptotic morphology (20). 
Antiphospholipid antibodies are directed to neo -
epitopes of oxidized phospholipids. Also, antiphos-
pholipid antibodies are directed against neoepitopes
generated during the formation of adduct products
between oxidized phospholipids and associated pro-
teins (17). 
It was proposed that in vivo b2gpI-phospholipid
interaction induces the formation of highly immuno-
genic phospholipid or protein epitopes. The different
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classes of antiphospholipid antibodies are directed
against oxidation-dependent and oxidation-independ-
ent neoepitopes. Some antiphospholipid antibodies
recognized oxLDL and this potential cross-reactivity
could be explained by the observation that oxLDL
represent a source of both phospholipid and protein
oxidized derivatives (21). 
Annexins
Annexins are a group of proteins that can bind
to negatively charged phospholipids in a calcium-
dependent and reversible manner (22). Their homo -
logy is located in a conserved core domain including
four homologous repeat sequences (65 to 70 amino -
acids long) (23). Annexins have predominantly in -
tracellular localization (suggested by the absence of
clas sical signal sequences in their polypeptide
chains). 
Annexin A5
Annexin A5 is present in cells exposed to blood
(platelets, trophoblasts and endothelial cells) (24,
25). It is an anticoagulant of 35.7 kDa (26).
The tertiary structure of anxA5 consists of a core
of four domains that are arranged in a cyclic array.
This arrangement gives the molecule a slightly curved
shape with a convex and a concave face. The do -
mains within the anxA5 molecule interact with each
other via non-covalent interactions. The interdomain
interactions result in the formation of two associated
modules consisting of domains IV and I, and domains
II and III. The interactions between domain I and IV
are mediated in a non-covalent manner by the amino -
terminal tail. Domains II and III are covalently linked
via a short inter-helical turn (27). Domain III is the
most distant from the membrane surface, while do -
main II is the closest (28, 29). All four do mains con-
tain Ca2+- dependent binding motifs (28). 
The Ca2+ and phosphatidylserine binding sites
are located at the convex, membrane-facing side of
the protein (30, 31). A short aminoterminal tail is
located at the concave side of the molecule. N-termi-
nal tail is recognized as the binding site for various lig-
ands (phospholipase A2, heparin, etc.). 
In solution, anxA5 molecules are monomers,
but upon binding to phosphatidylserine-expressing
membranes, they form trimers. This is followed by the
formation of a two-dimensional crystal lattice. Mem -
brane-bound annexin A5 assembles into a trimer
which is organized in such a way that domain II of
each individual molecule is located in the centre of a
trimer (32). 
The capacity of annexin A5 to bind to phos-
phatidylserine has led to a proposal that annexin A5
has antithrombotic features (33, 34). Annexin A5
competes with Va, Xa and prothrombin for binding to
phosphatidylserine and prevents formation of the pro-
thrombinase complex and consequently formation of
thrombin (35). Also, it was proposed that annexin A5
forms a twodimensional lattice on the phosphati dyl -
serine expressing surface and prevents formation of
thrombin (36). Anticoagulant properties of annexin
A5 in vitro have been described (37, 38), but the
physiological function of a low concentration of cir -
culating levels of annexin A5 is not clear yet (25). 
Annexin A5 can inhibit phospholipase A2
(PLA2) in cytosolic and also in soluble forms (39).
Phospholipase A2 is an enzyme important in pros ta -
glandin synthesis and in the generation of inflamma-
tory phospholipids (40, 41). This enzyme is present in
atherosclerotic lesions (42, 43). 
Inhibition of annexin A5 binding may increase
PLA2 activity, and, as a consequence, this leads to
raised production of inflammatory lipids (44). In addi-
tion, annexin A5 binds to proteoglycans in the arteri-
al wall and this might be an important early step in
atherogenesis (45). 
In a rabbit carotid artery injury model, it was
demonstrated that arterial thromboses could be inhib-
ited by recombinant annexin A5 (46). It was suggest-
ed that annexin A5 might be used as a therapeutic
agent that reduces the risk of plaque rupture and
atherothrombosis by covering exposed procoagulant
surfaces in the plaque (44).
Annexin A5 binds to apical surfaces of placental
syntitiotrophoblasts and could therefore be important
for the maintenance of blood flow through the pla-
centa (47). Annexin A5 is deficient in placentas from
patients with APS. Also, it is deficient in cultured tro-
phoblasts and endothelial cells exposed to anti -
phospholipid antibodies. It was reported that anxA5
forms an antithrombotic shield around procoagulant
anionic phospholipids (which blocks their participa-
tion in phospholipid-dependent coagulation reac-
tions), but in APS patients formation of this anti -
throm botic shield is disrupted by antibodies with
spe cificities against phospholipid-binding proteins.
Annexin A5 was used as an agent for molecular
imaging techniques (visualization of phospha ti dyl -
serine-expressing apoptotic cells) in vitro and in vivo in
animal models and in patients (injection of human
recombinant anxA5 into a patient‘s circulation.
Anti-Annexin A5 Antibodies
Annexinopathies are disorders characterized by
deregulation of annexin expression levels and func-
tion (48). It was suggested that anti-annexin A5 anti-
bodies might be the cause of thrombotic events inter-
fering with the functions of anxA5 (49, 50).
Anti-annexin A5 antibodies cause placental
thrombosis and fetal absorption in mice (51), while
some authors reported no association between anti-
annexin A5 antibodies and a history of thrombosis
(52). Weak, but statistically significant correlation be -
tween the IgM isotype of anti-annexin A5 antibodies
and adiponectin concentrations was found in type II
diabetes mellitus patients (r = 0.285, p=0.011) (53).
Anti-annexin A5 antibodies have been detected
in patients with some systemic autoimmune diseases
(systemic lupus erythematosus, rheumatoid arthritis)
and this observation was associated with higher inci-
dences of intrauterine fetal loss, preeclampsia and
arte r ial and venous thromboses (54–57). Although
ele vated anti-annexin A5 antibody levels were found in
patients with different autoimmune diseases, the role
of anti-annexin A5 antibodies in PAPS has not been
explained yet. Previously, in a study which in cluded
192 patients with SLE and only six patients with PAPS,
it was found that detection of anti-annexin A5 antibo -
dies of the IgG and IgM isotype is not relevant for
identification of patients at risk for thrombosis (58). 
In agreement with the abovementioned in ves ti -
ga tion, in a study (59) which included 44 PAPS pa -
tients, no correlation between anti-annexin A5 anti-
bodies and arterial or venous thromboses was found.
Positive correlation was found between concentra-
tions of the IgM isotype of anticardiolipin antibodies,
anti-b2gpI antibodies and anti-annexin A5 antibodies
of the same isotype were found in PAPS patients (59).
Antiphospholipid antibodies can decrease the
binding of annexin A5 to the endothelium thereby
promoting atherothrombosis and its clinical manifes -
tations (myocardial infarctions, stroke) (60). However,
another study found no association between anti-
annexin A5 antibodies and myocardial infarctions in
patients with primary antiphospholipid syndrome (59). 
PAPS patients with pulmonary emboli showed a
positive correlation between IgM isotype of anti-
annexin A5 antibodies and TNF-alpha (r = 0.894, p
= 0.041) (61). In PAPS with cerebrovascular insults a
positive correlation was noticed between TNF-alpha
and the IgG isotype of anti-annexin A5 Abs (r =
0.768, p = 0.006) (61). Isotype analysis of antiphos-
pholipid and anti-annexin A5 Abs and investigation of
their association with TNF-alpha is important for dif-
ferentiation of PAPS patients that are prone to further
deterioration of arterial and venous thromboses (61).
During placental development trophoblasts fuse
to form syncytiotrophoblast (62) which is accompa-
nied by surface expression of phosphatidylserine mak-
ing syntitium a potential site for activation of coagula-
tion processes (63, 47). Annexin A5 is abundantly
present on the syncytial surface and forms a twodi-
mensional lattice, thereby preventing the coagulation
process (64, 65). Antiphospholipid antibodies can
disrupt the organization of the annexin A5 twodimen-
sional lattice (66). 
It was reported that patients with APS had signif-
icantly reduced annexin A5 levels on placental villi
(64). Also, it was reported that antiphospholipid anti-
bodies decreased levels of annexin A5 on the sur-
faces of cultured trophoblasts and placental villi (67).
These findings suggest that reduced expression of
annexin A5 in placentas leads to a hypercoagulable
state in the intervillous space (57).
Exposure of anionic phospholipids is a substrate
for cationic annexin A5 binding which neutralizes pro-
coagulant phospholipids and increases antigen densi-
ty that is suitable for anti-annexin A5 antibodies (57).
Also, anti-annexin A5 antibodies have a role in preg-
nancy-associated complications, because 36% of
patients with habitual fetal loss had anti-annexin A5
antibodies. These antibodies were found in 20% of
patients with preeclampsia (68). The association
between anti-annexin A5 antibodies and abortions in
the general female population is controversial (69).
Only PAPS patients with a history of repeated
miscarriages have significantly elevated IgG anti-
annexin A5 antibody concentrations (OR = 4.788,
p = 0.036, 95% CI: 1.104–20.762). This finding
must be viewed with caution because it reflects a
small number of patients with recurrent abortions
(n=6) that were included in the study (59). There -
fore, it is possible that the IgG isotype of anti-annexin
A5 antibodies is a predictor of recurrent abortions in
PAPS. Also, these antibodies might occur after one or
more abortions, and thus represent an immunological
epi phenomenon of abortions (70).
Previously, it was reported that annexin A5 is
involved in lupus anticoagulant-induced apoptosis
because the IgG isotype of anti-annexin A5 antibod-
ies induced apoptosis of endothelial cells (71).
Monoclonal anti-annexin A5 antibodies reacting
with annexin A5 induced syncytiotrophoblast apo p tosis
in the primary trophoblast culture (57).
Although the determination of titers of anti-
annexin A5 antibodies is not mandatory for the diag-
nosis of the antiphospholipid syndrome, it was report-
ed that patients with primary antiphospholipid
syn drome with a history of recurrent abortions had
elevated titers of anti-annexin A5 antibodies, while
the presence of thromboses was not associated with
elevated levels of these antibodies.
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